Loading...
Loading...
India's liraglutide imports from DENMARK total $157.8M across 23 shipments from 5 foreign suppliers. M S NOVO NORDISK A S leads with $121.9M in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include NOVO NORDISK INDIA PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for liraglutide โ a diversified sourcing base with multiple active suppliers from DENMARK.

M S NOVO NORDISK A S is the leading Liraglutide supplier from DENMARK to India, with import value of $121.9M across 4 shipments. The top 5 suppliers โ M S NOVO NORDISK A S, M/S. NOVO NORDISK A/S, MS NOVO NORDISK A/S, RX SOURCE LIMITED, E-PHARM LIMITED โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | M S NOVO NORDISK A S | $121.9M | 4 | 77.2% |
| 2 | M/S. NOVO NORDISK A/S | $35.1M | 11 | 22.3% |
| 3 | MS NOVO NORDISK A/S | $796.8K | 3 | 0.5% |
| 4 | RX SOURCE LIMITED | $10.8K | 2 | 0.0% |
| 5 | E-PHARM LIMITED | $4.4K | 3 | 0.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | NOVO NORDISK INDIA PRIVATE LIMITED | $157.8M | 18 | 100.0% |
| 2 | BIOLOGICAL E. LIMITED | $10.8K | 2 | 0.0% |
| 3 | DR.REDDY'S LABORATORIES LTD |
DENMARK โ India trade corridor intelligence
The Denmark to India trade corridor is currently stable, with no significant port congestion reported at major Indian ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra. Freight rates are consistent with historical averages, and the exchange rate between the Indian Rupee (INR) and Danish Krone remains favorable for trade. No major disruptions have been reported in the supply chain for Liraglutide formulations.
The PLI scheme, introduced in 2020, aims to boost domestic manufacturing and may impact the import of finished formulations, including Liraglutide, by encouraging local production. Import substitution policies are being considered to reduce dependency on imports, but the transition is gradual, and imported formulations continue to play a crucial role in meeting market demand.
India and Denmark maintain strong trade relations, with ongoing discussions to enhance pharmaceutical trade. While there is no specific Free Trade Agreement (FTA) between the two countries, mutual recognition of Good Manufacturing Practice (GMP) standards is being explored to facilitate smoother trade. Efforts are underway to streamline regulatory processes and improve trade facilitation for pharmaceutical products.
| $4.4K |
| 3 |
| 0.0% |
The landed cost of importing Liraglutide formulations from Denmark to India includes the following components:
Per-unit estimates depend on order size and specific product details.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Liraglutide into India, obtaining an import license from the Directorate General of Foreign Trade (DGFT) is mandatory. The Central Drugs Standard Control Organisation (CDSCO) requires registration of the product, which involves submitting Form 40/41 along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The registration process typically takes 6โ12 months, depending on the completeness of the application and compliance with regulatory requirements. Liraglutide formulations under HS Code 30049099 are subject to these regulations to ensure quality, safety, and efficacy.
Imported Liraglutide formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to International Council for Harmonisation (ICH) Zone IV guidelines, is essential to demonstrate product stability under Indian climatic conditions. Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported products.
In April 2025, the CDSCO mandated import registration and licensing for all pharmaceutical imports to prevent the sale of unapproved or illegal medicines in the Indian market. This regulation requires compliance with the Drugs and Cosmetics Act and associated rules. Additionally, the Production Linked Incentive (PLI) scheme, introduced in 2020, aims to boost domestic manufacturing and may impact the import of finished formulations, including Liraglutide, by encouraging local production.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Liraglutide formulations primarily due to the availability of patented or branded products not manufactured domestically. Specific dosage forms, such as pre-filled pens and cartridges, are often sourced from international markets. Domestic capacity for Liraglutide formulations is limited, leading to a dependency on imports to meet patient needs. The market size for Liraglutide in India is growing, driven by increasing prevalence of Type 2 diabetes and the need for effective management options.
The Basic Customs Duty (BCD) for Liraglutide formulations under HS Code 30049099 is 10%. A Social Welfare Surcharge (SWS) of 10% on BCD is applicable. Integrated Goods and Services Tax (IGST) is levied as per prevailing rates, which are subject to change. There are no specific exemptions or concessional duties for Denmark-origin products under the Most Favored Nation (MFN) tariff. The total landed duty percentage varies based on the IGST rate and other applicable charges.
Denmark, particularly through Novo Nordisk, is a significant supplier of Liraglutide formulations to India. The competitive advantage lies in the availability of patented formulations and specialized dosage forms not produced domestically. Other suppliers include China, Germany, and the United States; however, Denmark's share is notable due to its established presence and quality standards.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Liraglutide formulations from Denmark due to the availability of patented products and specialized dosage forms not manufactured domestically. Denmark's established pharmaceutical industry, particularly through Novo Nordisk, offers high-quality products that meet international standards, fulfilling the unmet demand in the Indian market.
Compared to other origins like China, Germany, and the United States, Denmark offers a competitive advantage in terms of product quality, regulatory compliance, and reliability. Denmark's adherence to stringent GMP standards and its reputation for innovation in diabetes care make it a preferred source for Liraglutide formulations.
Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. While Denmark has a stable supply chain, Indian importers should consider these factors in their risk management strategies.
Import license checklist, document requirements, quality testing, and compliance
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Liraglutide suppliers from DENMARK to India include M S NOVO NORDISK A S, M/S. NOVO NORDISK A/S, MS NOVO NORDISK A/S. The leading supplier is M S NOVO NORDISK A S with import value of $121.9M USD across 4 shipments. India imported Liraglutide worth $157.8M USD from DENMARK in total across 23 shipments.
India imported Liraglutide worth $157.8M USD from DENMARK across 23 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Liraglutide sourced from DENMARK include NOVO NORDISK INDIA PRIVATE LIMITED, BIOLOGICAL E. LIMITED, DR.REDDY'S LABORATORIES LTD. The largest buyer is NOVO NORDISK INDIA PRIVATE LIMITED with $157.8M in imports across 18 shipments.
The total value of Liraglutide imports from DENMARK to India is $157.8M USD, across 23 shipments and 5 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
23 Verified Shipments
5 suppliers, 3 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists